R. Aron English - Apr 21, 2022 Form 4 Insider Report for Anebulo Pharmaceuticals, Inc. (ANEB)

Role
Director, 10%+ Owner
Signature
/s/ Aron R. English
Stock symbol
ANEB
Transactions as of
Apr 21, 2022
Transactions value $
$4,999,998
Form type
4
Date filed
9/30/2022, 09:36 PM
Previous filing
Dec 21, 2021
Next filing
Jul 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANEB Common Stock Award $4.79M +1.7M +50.66% $2.81 5.07M Sep 28, 2022 22NW Fund, LP F1, F2
holding ANEB Common Stock 4.65M Apr 21, 2022 Pharma Investors, LLC F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANEB Stock Option (right to buy) Award $0 +30.4K $0.00 30.4K Apr 21, 2022 Common Stock 30.4K $6.00 Direct F4
transaction ANEB Common Stock Purchase Warrant (right to buy) Award $213K +1.7M $0.13* 1.7M Sep 28, 2022 Common Stock 1.7M $4.22 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is filed jointly by Aron R. English and 22NW Fund, LP (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F2 Securities owned directly by 22NW Fund, LP. Mr. English, as the Manager of 22NW Fund GP, LLC, which is the General Partner of 22NW Fund, LP, may be deemed to beneficially own the securities owned directly by 22NW Fund, LP.
F3 Securities owned directly by Pharma Investors, LLC. Mr. English, as the owner of Pharma Investors, LLC, may be deemed to beneficially own the securities owned directly by Pharma Investors, LLC.
F4 25% of the option vests on March 1, 2023. Thereafter, 1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested.